Search results
Showing 286 to 300 of 2548 results for methods
In development Reference number: GID-TA10227 Expected publication date: TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]
In development Reference number: GID-TA10225 Expected publication date: TBC
In development Reference number: GID-TA10446 Expected publication date: TBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340
In development Reference number: GID-TA10313 Expected publication date: TBC
In development Reference number: GID-TA10326 Expected publication date: TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development Reference number: GID-TA10573 Expected publication date: TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development Reference number: GID-TA10623 Expected publication date: TBC
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Evidence-based recommendations on bosutinib (Bosulif) for previously reated chronic myeloid leukaemia in adults.
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Laparoscopic renal denervation for loin pain haematuria syndrome (IPG709)
Evidence-based recommendations on laparoscopic renal denervation for loin pain haematuria syndrome in adults. This involves the stripping away of nerves from the kidney using keyhole surgery to relieve pain.
View recommendations for IPG709Show all sections
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Awaiting development Reference number: GID-TA10774 Expected publication date: TBC
This quality standard covers assessing and treating fertility problems in people with explained and unexplained infertility, including access to IVF treatment. It also covers cryopreservation before cancer treatment that may affect fertility. It describes high-quality care in priority areas for improvement.
View quality statements for QS73Show all sections
Sections for QS73
- List of quality statements
- Quality statement 1: Lifestyle advice
- Quality statement 2: Referral for specialist consultation
- Quality statement 3: Counselling
- Quality statement 4: Semen analysis
- Quality statement 5: IVF for women under 40 years
- Quality statement 6: IVF for women aged 40 to 42 years
- Quality statement 7: Intracytoplasmic sperm injection
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Awaiting development Reference number: GID-TA10682 Expected publication date: TBC
In development Reference number: GID-TA10311 Expected publication date: TBC